- European regulators endorsed Foundayo, Lilly's oral weight-loss pill, and LLY stock surged, per H5 coverage.
- Mounjaro and Zepbound generated nearly two-thirds of Q2 revenue; Foundayo recorded $98 million.
- Q2 revenue was $22.97 billion, up 47.7% year over year, and Lilly raised full-year guidance.
- The Medicare GLP-1 Bridge program offers $50/month co-pays for obesity drugs and is a near-term catalyst for prescriptions.
- LLY trades at about 44 times trailing earnings and 35 times 2026 EPS estimates.
- Metis TechBio agreed a collaboration with Lilly worth up to $1.1 billion, with an upfront payment in the low double-digit millions of US dollars.
- Lilly will announce Q3 2026 results on October 29, 2026, with a 10 a.m. Eastern conference call.
Quotes
“collaboration agreement with Eli Lilly worth up to $1.1 billion to research and develop tissue-specific drug delivery technologies”